Based on 1 analyst offering 12 month price targets for Dermata Therapeutics Inc
Min Forecast
$10.00+296.83%
Avg Forecast
$10.00+296.83%
Max Forecast
$10.00+296.83%
Should I buy or sell DRMA stock?
Based on 1 analyst offering ratings for Dermata Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DRMA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DRMA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More
Be the first to know when Wall Street analysts revise their DRMA stock forecasts and price targets.
Is Dermata Therapeutics Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: DRMA) stock is to Strong Buy DRMA stock.
Out of 1 analyst, 1 (100%) are recommending DRMA as a Strong Buy, 0 (0%) are recommending DRMA as a Buy, 0 (0%) are recommending DRMA as a Hold, 0 (0%) are recommending DRMA as a Sell, and 0 (0%) are recommending DRMA as a Strong Sell.
What is DRMA's earnings growth forecast for 2026-2026?
(NASDAQ: DRMA) Dermata Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Dermata Therapeutics's earnings in 2026 is -$8,847,607.
In 2026, DRMA is forecast to generate -$3,151,428 in earnings, with the lowest earnings forecast at -$3,027,843 and the highest earnings forecast at -$3,244,117.
What is DRMA's revenue growth forecast for 2026-2026?
(NASDAQ: DRMA) Dermata Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Dermata Therapeutics's revenue in 2026 is $0.
In 2026, DRMA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.
What is DRMA's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: DRMA) forecast ROA is -62.14%, which is lower than the forecast US Biotechnology industry average of 18.03%.
What is DRMA's Price Target?
According to 1 Wall Street analyst that have issued a 1 year DRMA price target, the average DRMA price target is $10.00, with the highest DRMA stock price forecast at $10.00 and the lowest DRMA stock price forecast at $10.00.
The Wall Street analyst predicted that Dermata Therapeutics's share price could reach $10.00 by Aug 21, 2026. The average Dermata Therapeutics stock price prediction forecasts a potential upside of 296.83% from the current DRMA share price of $2.52.
What is DRMA's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: DRMA) Dermata Therapeutics's current Earnings Per Share (EPS) is $14.19. In 2026, DRMA's EPS is forecast to hit -$3.07 (min: -$2.95, max: -$3.16).
What is DRMA's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: DRMA) forecast ROE is -79.58%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.